Literature DB >> 7506408

Expanding multiple marker screening for Down's syndrome to include Edward's syndrome.

G Barkai1, B Goldman, L Ries, R Chaki, T Zer, H Cuckle.   

Abstract

Information on maternal age and maternal serum alpha-fetoprotein, unconjugated oestriol (uE3), and human chorionic gonadotrophin (hCG) levels was used to investigate retrospectively the effect of estimating Edward's syndrome risk in women having multi-marker screening for Down's syndrome. The screened population comprised 15 pregnancies affected by Edward's syndrome, 15 with Down's syndrome and 5472 unaffected pregnancies. The use of all three markers to estimate Edward's syndrome risk would have led to the detection of 10-12 (67-80 per cent) cases with a false-positive rate of 0.3-0.6 per cent depending on the risk cut-off. A further case would have been detected as a result of screening for Down's syndrome alone. Similar results were obtained when the Edward's syndrome risk was based on uE3 and hCG only. These data suggest that extending Down's syndrome screening to include Edward's syndrome risk will yield a high detection rate with only a small increase in the false-positive rate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506408     DOI: 10.1002/pd.1970130908

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  4 in total

1.  Update and Review: Maternal Serum Screening.

Authors:  K E Ormond
Journal:  J Genet Couns       Date:  1997-12       Impact factor: 2.537

2.  NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.

Authors:  K L Wilson; J L Czerwinski; J M Hoskovec; S J Noblin; C M Sullivan; A Harbison; M W Campion; K Devary; P Devers; C N Singletary
Journal:  J Genet Couns       Date:  2012-11-22       Impact factor: 2.537

Review 3.  Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening.

Authors:  Amy Metcalfe; Catriona Hippman; Melanie Pastuck; Jo-Ann Johnson
Journal:  J Clin Med       Date:  2014-04-08       Impact factor: 4.241

4.  Impact of Cell-Free Fetal DNA Screening on Patients' Choice of Invasive Procedures after a Positive California Prenatal Screen Result.

Authors:  Forum T Shah; Kathryn Steinhaus French; Kathryn E Osann; Maureen Bocian; Marilyn C Jones; Lauren Korty
Journal:  J Clin Med       Date:  2014-07-24       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.